4.1 Article

Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core

Journal

PROTEIN ENGINEERING DESIGN & SELECTION
Volume 22, Issue 7, Pages 421-430

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/protein/gzp018

Keywords

drug design; folding intermediate; p53; protein stability; structure

Funding

  1. Singapore Agency for Science, Technology and Research
  2. Cancer Research, UK
  3. Medical Research Council
  4. EC FP6
  5. MRC [MC_U105474168] Funding Source: UKRI
  6. Medical Research Council [MC_U105474168] Funding Source: researchfish

Ask authors/readers for more resources

The core domain of the tumour suppressor p53 is of inherently low thermodynamic stability and also low kinetic stability, which leads to rapid irreversible denaturation. Some oncogenic mutations of p53 act by just making the core domain thermosensitive, and so it is the target of novel anti-cancer drugs that bind to and stabilise the protein. Increasing the stability of the unstable core domain has also been crucial for biophysical and structural studies, in which a stabilised quadruple mutant (QM) is currently used. We generated an even more stabilised hexamutant (HM) by making two additional substitutions, Y236F and T253I, to the QM. The residues are found in the more stable paralogs p63 and p73 and stabilise the wild-type p53 core domain. We solved the structure of the HM core domain by X-ray crystallography at 1.75 A resolution. It has minimal structural changes from QM that affect the packing of hydrophobic core residues of the beta-sandwich. The full-length HM was also fully functional in DNA binding. HM was more stable than QM at 37 degrees C. Anomalies in biophysics and spectroscopy in urea-mediated denaturation curves of HM implied the accumulation of a folding intermediate, which may be related to those detected in kinetic experiments. The two additional mutations over-stabilise an unfolding intermediate. These results should be taken into consideration in drug design strategies for increasing the stability of temperature-sensitive mutants of p53.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm

Matthias R. Bauer, Andreas Kraemer, Giovanni Settanni, Rhiannon N. Jones, Xiaomin Ni, Raysa Khan Tareque, Alan R. Fersht, John Spencer, Andreas C. Joerger

ACS CHEMICAL BIOLOGY (2020)

Article Oncology

Characterization of a dualBET/HDACinhibitor for treatment of pancreatic ductal adenocarcinoma

Xin Zhang, Tim Zegar, Tim Weiser, Feda H. Hamdan, Benedict-Tilman Berger, Romain Lucas, Dimitrios-IIias Balourdas, Swetlana Ladigan, Phyllis F. Cheung, Sven-Thorsten Liffers, Marija Trajkovic-Arsic, Bjoern Scheffler, Andreas C. Joerger, Stephan A. Hahn, Steven A. Johnsen, Stefan Knapp, Jens T. Siveke

INTERNATIONAL JOURNAL OF CANCER (2020)

Article Biochemistry & Molecular Biology

Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene

Flora Doffe, Vincent Carbonnier, Manon Tissier, Bernard Leroy, Isabelle Martins, Johanna S. M. Mattsson, Patrick Micke, Sarka Pavlova, Sarka Pospisilova, Jana Smardova, Andreas C. Joerger, Klas G. Wiman, Guido Kroemer, Thierry Soussi

Summary: Infrequent and rare genetic variants in the human population outnumber common ones significantly. The TP53 coding region shows far more polymorphism than previously thought and presents high ethnic diversity. Analyses of new missense TP53 variants revealed they are benign and do not display loss of function compared to the normal TP53 gene.

CELL DEATH AND DIFFERENTIATION (2021)

Article Chemistry, Medicinal

Selective targeting of the αC and DFG-out pocket in p38 MAPK

Sandra Roehm, Martin Schroeder, Jessica E. Dwyer, Caroline S. Widdowson, Apirat Chaikuad, Benedict-Tilman Berger, Andreas C. Joerger, Andreas Kraemer, Jule Harbig, Daniel Dauch, Mark Kudolo, Stefan Laufer, Mark C. Bagley, Stefan Knapp

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)

Article Chemistry, Medicinal

Pan-SMARCA/PB1 Bromodomain Inhibitors and Their Role in Regulating Adipogenesis

Marek Wanior, Franziska Preuss, Xiaomin Ni, Andreas Kraemer, Sebastian Mathea, Tamara Goebel, David Heidenreich, Svenja Simonyi, Astrid S. Kahnt, Andreas C. Joerger, Stefan Knapp

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Article Biochemistry & Molecular Biology

Genotoxicity and Epigenotoxicity of Carbazole-Derived Molecules on MCF-7 Breast Cancer Cells

Claudio Luparello, Ilenia Cruciata, Andreas C. Joerger, Cory A. Ocasio, Rhiannon Jones, Raysa Khan Tareque, Mark C. Bagley, John Spencer, Martin Walker, Carol Austin, Tiziana Ferrara, Pietro D' Oca, Rossella Bellina, Rossella Branni, Fabio Caradonna

Summary: Carbazole compounds PK9320 and PK9323, as second-generation analogues of PK083, have been shown to restore p53 signaling in cancer cells by binding to mutation-induced surface crevices. The study demonstrates that small modifications in carbazole substitution patterns can significantly impact their genotoxic and epigenetic properties, with PK9320 and PK9323 being potential candidates for anticancer and epi-compounds.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Review Biochemistry & Molecular Biology

Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy

Marek Wanior, Andreas Kraemer, Stefan Knapp, Andreas C. Joerger

Summary: SWI/SNF complexes are crucial epigenetic regulators of gene transcription, with a high mutation prevalence in human cancers driving oncogenic programs. SWI/SNF-mutant cancers are hypersensitive to perturbations in other subunits and biological pathways, offering potential for sustained anticancer effects. Exploiting these vulnerabilities through targeted therapy strategies, such as proteolysis targeting chimeras, can induce synthetic lethality in SWI/SNF-deficient cancers.

ONCOGENE (2021)

Article Chemistry, Medicinal

Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe

Sandra Roehm, Benedict-Tilman Berger, Martin Schroeder, Deep Chatterjee, Sebastian Mathea, Andreas C. Joerger, Daniel M. Pinkas, Joshua C. Bufton, Amelie Tjaden, Lohitesh Kovooru, Mark Kudolo, Christian Pohl, Alex N. Bullock, Susanne Mueller, Stefan Laufer, Stefan Knapp

Summary: In this study, a potent and cell-active dual DDR/p38 chemical probe was developed, along with a structurally related negative control, for studying DDR kinase signaling. The structure-guided design approach provided insights into the folding process of p38 and how non-conserved amino acids modulate inhibitor selectivity. The developed DDR/p38 probe is a valuable tool for investigating the role of DDR kinase in normal physiology and disease development.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Chemistry, Medicinal

Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors

Roberta Tesch, Marcel Rak, Monika Raab, Lena M. Berger, Thales Kronenberger, Andreas C. Joerger, Benedict-Tilman Berger, Ismahan Abdi, Thomas Hanke, Antti Poso, Klaus Strebhardt, Mourad Sanhaji, Stefan Knapp

Summary: Salt-inducible kinases (SIKs) are crucial metabolic regulators, with their imbalance linked to various cancers. Researchers have optimized a kinase inhibitor to target SIK specifically, providing a potential new approach for cancer therapy by combining SIK inhibitors with traditional chemotherapeutic agents like paclitaxel.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

Article Cell Biology

Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog

Qiang Zhang, Dimitrios-Ilias Balourdas, Bruno Baron, Alon Senitzki, Tali E. Haran, Klas G. Wiman, Thierry Soussi, Andreas C. Joerger

Summary: The extremophile Alvinella pompejana, an annelid worm living near hydrothermal vents in the Pacific Ocean, has a p53 family gene with a highly thermostable DNA-binding domain, which may play a crucial role in maintaining genome integrity.

CELL DEATH & DISEASE (2022)

Article Chemistry, Medicinal

Development of a Potent Cyclic Peptide Inhibitor of the nNOS/PSD-95 Interaction

Javier R. Balboa, Dominik J. Essig, Sana Ma, Nichlas Karer, Louise S. Clemmensen, Soren W. Pedersen, Andreas C. Joerger, Stefan Knapp, Soren Ostergaard, Kristian Stromgaard

Summary: The complex of NMDAR, nNOS, and PSD-95 is an important therapeutic target for acute ischemic stroke. By designing a cyclic nNOS β-hairpin mimetic peptide and generating peptide arrays, a potent inhibitor of the nNOS/PSD-95 interaction was identified.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Biochemistry & Molecular Biology

Structural insights into a regulatory mechanism of FIR RRM1-FUSE interaction

Xiaomin Ni, Andreas C. Joerger, Apirat Chaikuad, Stefan Knapp

Summary: FUBP-interacting repressor (FIR) is a suppressor of the proto-oncogene MYC's transcription, by binding to the far upstream element (FUSE) of the MYC promoter. Competition with FUSE-binding protein 1 (FUBP1) is a crucial mechanism for MYC transcriptional regulation.

OPEN BIOLOGY (2023)

Article Biochemical Research Methods

Structure-Reactivity Studies of 2-Sulfonylpyrimidines Allow Selective Protein Arylation

Maeva M. Pichon, Dawid Drelinkiewicz, David Lozano, Ruxandra Moraru, Laura J. Hayward, Megan Jones, Michael A. Mccoy, Samuel Allstrum-Graves, Dimitrios-Ilias Balourdas, Andreas C. Joerger, Richard J. Whitby, Stephen M. Goldup, Neil Wells, Graham J. Langley, Julie M. Herniman, Matthias G. J. Baud

Summary: Protein arylation using 2-sulfonylpyrimidines as covalent warheads for selective and metal-free cysteine S-arylation was evaluated. The reaction resulted in stable S-heteroarylated adducts at neutral pH. Fine-tuning of the heterocyclic core and exocyclic leaving group allowed predictable reactivity, covering >9 orders of magnitude. This study provides a comprehensive structure-reactivity relationship on heteroaryl sulfones and highlights 2-sulfonylpyrimidine as a synthetically tractable and protein compatible covalent motif for targeting reactive cysteines.

BIOCONJUGATE CHEMISTRY (2023)

Article Chemistry, Medicinal

Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C

Joseph R. Stephenson Clarke, Leon R. Douglas, Patrick J. Duriez, Dimitrios-Ilias Balourdas, Andreas C. Joerger, Raniya Khadiullina, Emil Bulatov, Matthias G. J. Baud

Summary: The tumor suppressor protein p53 is inactivated in the majority of human cancers, and the Y220C mutant is one of the most prevalent p53 mutants. This study presents the development of high-affinity small molecules to stabilize p53-Y220C, marking an important milestone in the search for effective anticancer therapies.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)

Article Biochemistry & Molecular Biology

Integrated analysis of Shank1 PDZ interactions with C-terminal and internal binding motifs

Muhammad Ali, Mishal Mariam McAuley, Susanne Luechow, Stefan Knapp, Andreas C. Joerger, Ylva Ivarsson

Summary: PDZ domains are a large family of modular domains known for binding C-terminal motifs of target proteins, but the interaction involving internal PDZ binding motifs (PDZbms) remains poorly studied. Using the PDZ domain of Shank1 as a model, this study explored internal PDZbm-mediated interactions, expanding the interactome of Shank1 and indicating a largely unexplored interaction space of PDZ domains. The findings revealed that both C-terminal and internal PDZbm interactions can occur in the context of full-length proteins, and the affinities of PDZbm interactions are in the low micromolar range.

CURRENT RESEARCH IN STRUCTURAL BIOLOGY (2021)

No Data Available